Search results for "Ladder"
showing 10 items of 674 documents
CORSO Carcinoma vescicale non muscolo invasivo : qualità del trattamento endoscopico
2014
Sebbene la resezione endoscopica per via transuretrale (TURBT) rappresenti lo standard per la diagnosi, la stadiazione e il primo trattamento delle neoplasie vescicali, la sua efficacia rimane ad oggi limitata a causa di numerose limitazioni intrinseche alla stessa procedura. I principali limiti oncologici della TURBT sono rappresentati da – violazione della asportazione en bloc della neoplasia, -inefficacia nei confronti delle lesioni piatte o non riconoscibile endoscopicamente, -incompletezza della resezione. Anche la qualità della esecuzione tecnica della resezione, in mancanza di adeguati standard e programmi di insegnamento è ridotta in moltissimi contesti clinici. Di conseguenza, la T…
Cigarette smoking and drinking water source: Correlation with clinical features and pathology of superficial bladder carcinoma.
2009
Is the efficacy of intravescical chemotherapy influenced by cigarette smoking? Data obtained in intermediate risk non muscle invasive bladder carcino…
2011
Aim of the study To study recurrence-free rate (RFR) and recurrence-free survival (RFS) according to the smoking status in patients affected by non-muscle invasive carcinoma of the bladder (NMI-BC) treated by intravesical chemotherapy. Materials and methods Smoking status was recorded at study entry. Intravesical epirubicin was administered within 6 hours from TUR at the dose of 80 mg diluted in 50 ml of saline solution. Further adjuvant treatment in low-risk and high-risk patients was given according to physicians’ choice. The remaining patients, at intermediate risk for recurrence, were randomized between two different schemes of intravesical chemotherapy: 5 more weekly instillations (tot…
SMOKING STATUS, RECURRENCE RISK AND INTRAVESICAL CHEMOTHERAPY IN NONMUSCLE- INVASIVE BLADDER CANCER
2011
Background and Aim: The influence of smoking status on the diagnosis of carcinoma of the bladder, on recurrence risk Abstracts of the 21st Annual Meeting of the Italian Society of Uro-Oncology (SIUrO), 22-24 June, 2011, Naples, Italy and response to intravesical treatment has been scarcely studied. Available studies suggest a reduction in recurrence risk with cessation of smoking, however, most studies lack sufficient statistical power. The aim of the present analysis was to study the recurrence risk and the response to intravesical chemotherapy in terms of recurrence-free rate (RFR) and recurrence-free survival (RFS) in relation to smoking status at diagnosis in patients affected by interm…
A PROSPECTIVE STUDY ON THE INFLUENCE ON RECURRENCE OF QUITTING CIGARETTE SMOKING AT DIAGNOSIS OF PRIMARY NON MUSCLE INVASIVE BLADDER CANCER
2015
IMPACT OF THE SITE OF RECURRENCE AFTER RADICAL CYSTECTOMY ON SURVIVAL: DIFFERENT SITES FOR DIFFERENT OUTCOMES
2015
VARIANT HISTOLOGIC DIFFERENTIATION IN BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY: INCIDENCE AND LONG TERM SURVIVAL IN A SINGLE INSTITUTION STUDY.
2016
LIMITS OF TRANSURETHRAL RESECTION IN DETECTING UNCOMMON HISTOLOGICAL VARIANTS WITHIN BULKY BLADDER TUMORS IN REAL-LIFE CLINICAL PRACTICE
2017
CHOICE OF ADJUVANT INTRAVESICAL THERAPY IN RECURRING INTERMEDIATE-RISK NMI-BC
2011
Objective: The therapeutic strategy for patients affected by intermediate risk non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy is not definitively established. Only few studies have been published on secondline intravesical therapy. BCG is advocated when intravesical chemotherapy fails and is often repeated. On the other hand, some patients that suffer recurrence repeat intravesical chemotherapy. A retrospective analysis of 179 intermediaterisk patients submitted to second-line intravesical therapy is reported. Patients and Methods: The clinical files of patients affected by intermediate risk NMI-BC and submitted to second-line adjuvant intravesical therapy w…